ExploreWatchlistsPricing
  1. JP-listed companies
  2. OncoTherapy Science, Inc.
  3. Financials
  4. Total non-current liabilities

OncoTherapy Science, Inc. (4564)

Market cap
¥6.4B
P/E ratio
OncoTherapy Science develops cancer treatments using genetic research, including targeted drugs, immunotherapies, and precision medicine testing for personalized cancer care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal non-current liabilities (Million JPY)YoY (%)
Mar 31, 202598-36.14%
Mar 31, 2024154+227.38%
Mar 31, 202347-52.97%
Mar 31, 2022100+3.82%
Mar 31, 202196-17.44%
Mar 31, 2020117-9.62%
Mar 31, 2019129-4.74%
Mar 31, 2018136+14.33%
Mar 31, 2017119-33.10%
Mar 31, 2016177-14.26%
Mar 31, 2015207

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat